BridgeBio Oncology Therapeutics Stock Forecast
NASDAQ: BBOTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 12:02 PM ET
BBOT analyst consensus
Consensus (12 analysts)
none
Avg. price target
$24.55+648.48%
- Strong buy 4
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 12 Wall Street analysts covering BridgeBio Oncology Therapeutics (2026-10-08), 12 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $24.55, with a high estimate of $50.00 and a low estimate of $15.00. The average target implies upside of 648.5% from the current price of $3.28.
The spread between the highest and lowest targets is 233.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for BBOT.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 4 | 33% |
| Buy | 8 | 67% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $15.00 | +357.32% |
| Average target | $24.55 | +648.48% |
| High target | $50.00 | +1424.39% |